MedTrace Logo

Assessment of Safety and Efficacy of ARTHRUM 2.5% for Treatment of Painful Osteoarthritis of the Knee

NCT06228274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2024-01-29

No results posted yet for this study

Summary

ARTHRUM 2.5% MONO-INJECTION as symptomatic treatment by joint injection extends the conservative therapeutic arsenal in Knee osteoarthritis.

The reduction of functional limits and disabilities induced by knee osteoarthritis as well as improvement of quality of life of patients is a public health need registered amongst the priorities established by the French law of 9 August 2004 relative to Public Health policy. However, the response to this need is not limited to treatment with health products.

This prospective, open, multi-centre trial of the real-life efficacy of ARTHRUM 2.5% aims to demonstrate the efficacy of a single joint injection of this treatment on pain, during 6 months, in the symptomatic treatment of patients suffering from Knee osteoarthritis

Conditions

Interventions

DEVICE

ARTHRUM 2.5%

ARTHRUM 2.5%

Sponsors & Collaborators

  • BIOSTATEM

    collaborator UNKNOWN

  • LCA Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • DOMINIQUE BARON, MD · Centre de reeducation et de readaptation fonctionnelles en milieu marin de Trestel

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-09-30
Completion
2017-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06228274 on ClinicalTrials.gov